382: Which Subgroups of Patients are at risk to die from Prostate Cancer and Benefit from Immediate Androgen Deprivation if they are not Suitable for local Treatment with Curative intent of Newly Diagnosed Prostate Cancer T0-4 N0-2 MO (EORTC 30891)?

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

382: Which Subgroups of Patients are at risk to die from Prostate Cancer and Benefit from Immediate Androgen Deprivation if they are not Suitable for local Treatment with Curative intent of Newly Diagnosed Prostate Cancer T0-4 N0-2 MO (EORTC 30891)?

Cited by 2 publications

References 0 publications

Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer

Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer

Contemporary Role of Endocrine Treatment in Patients with Localized or Locally Advanced Prostate Cancer: A Review

Contact Info

Product

Resources

About